⏱️ What is the “door-to-needle” time for amyloid-targeting treatments? 🧠 A new paper led by Anna Hofmann from the Washington University Memory Diagnostic Center examined this in a real-world memory clinic setting. alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

Submit your research to #DADM Special Issue! 2nd Edition: Real-World Evidence on Amyloid-Targeting Treatments: Early Data on Clinical Implementation, Safety, and Efficacy ⏰Deadline: Oct. 31, 2026 alz-journals.onlinelibrary.wiley.com/hub/journal/... Guest Editor: @suzanneeschindler.bsky.social

1️⃣ A plasma model combining %p-tau217 and eMTBR-tau243 showed high concordance with PET-based biological staging across independent cohorts.

New publication in JAMA Neurology! 🧠 In this study, led by @gsalvado.bsky.social, we developed and validated a plasma-based biological staging model for Alzheimer’s disease using two blood biomarkers: %p-tau217 and eMTBR-tau243. jamanetwork.com/journals/jam...

🧠 Real-world data from the Washington University Memory Diagnostic Center on clinical use of Alzheimer's disease biomarker tests in 1,136 patients: doi.org/10.1002/alz.... Biomarker testing increased by 7-fold over four years; females and White individuals had higher rates of biomarker positivity.

New AI model can detect multiple cognitive brain diseases from a single blood sample www.lunduniversity.lu.se/article/new-... #Alzheimers #dementia #Parkinsons #ALS #FTD #stroke #science #NeuroSkyence #AI

This study was led by Beata Borgström Bolmsjö and Sebastian Palmqvist. A big thanks to all collaborators and co-authors! @suzanneeschindler.bsky.social

Biomarkers play a critical role in diagnosing Alzheimer’s disease.🧠 Join us on Feb. 26 at 1pm CT for a free webinar to learn about biomarkers,and get updates and tips to help you talk to your doctor and understand testing options. Register: https://bit.ly/4bGbapa.

🩸 🧠 ⏱️ What if a blood test could predict WHEN an individual would develop symptoms of Alzheimer’s disease? High plasma p-tau217 predicts greater risk for Alzheimer’s symptoms—do the plasma p-tau217 levels provide insights into WHEN symptoms might begin? nature.com/articles/s41...

The U.S. Is Funding Fewer Grants in Every Area of Science and Medicine www.nytimes.com/interactive/... #Alzheimers #dementia #science #neuroscience #NeuroSkyence

Animated educational videos for clinicians that describe how to use biomarkers for Alzheimer's disease in clinical practice. Neurology in Motion: practicalneurology.com/videos/neuro... #ENDALZ #dementia

ICYMI: New online! Towards pharmacological prevention of Alzheimer disease

That's exactly why Randall J. Bateman, MD, was invited to @cbssundaymorning.bsky.social — see how our groundbreaking clinical trials could change the outcome for millions of people who live in fear of what Alzheimer’s takes from them: campaigns.med.washu.edu/alz

The FDA has cleared the first blood test for Alzheimer’s for use in primary care settings to rule out the presence of amyloid. “This is another important step toward expanding access to Alzheimer’s diagnostic tools." -Joanne Pike, Association president & CEO Read our full statement: bit.ly/4oh3Tiu

My op-ed just came out discussing how NIH leadership is failing early career researchers and, importantly, how we can push back and take our future into our own hands.

Has your research funding been cut by the administration? Now is the time to raise your voices. I know we all know someone, even if we ourselves haven’t been personally affected (yet). Please share your story with @nytimes.com www.nytimes.com/2025/10/08/c...

New landscape of the diagnosis of Alzheimer's disease www.thelancet.com/journals/lan... by @thelancet.com #Alzheimers #dementia #biomarkers #neuroscience #NeuroSkyence

Review of Alzheimer's diagnostics from The Lancet: New landscape of the diagnosis of Alzheimer's disease www.sciencedirect.com/science/arti... #ENDALZ

We're proud to share that over the last year, we invested $112.2 million in our research programs—the largest single-year on record—bringing our total active & committed investments to over $450 million. Help us continue the momentum: alz.org/donate. #ENDALZ #BrainHealth

New paper from the lab. First author @mwelhaf.bsky.social, now in a TT position at North Carolina A&T. We wanted to know how environmental contexts and self-reported distractions impacted cognitive #EMA in older adults. mhealth.jmir.org/2025/1/e71578 1/n

"Clocks" that relate amyloid and tau PET to time were used to examine the timing of biomarker changes (including plasma biomarkers) in Alzheimer disease. Plasma Aβ42/40 changes very early! onlinelibrary.wiley.com/doi/10.1002/... #ENDALZ

Practical information for clinicians on selection and interpretation of different biomarker tests for Alzheimer disease: practicalneurology.com/diseases-dia...

Alzheimer's disease drug development pipeline: 2025 - Cummings - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library alz-journals.onlinelibrary.wiley.com/doi/10.1002/...

From clinical trials to practice, WashU Medicine’s Memory Diagnostic Center offers top-tier, end-to-end Alzheimer's care. Now, a promising new study paves the way for clinics worldwide to adopt our elevated standard of outpatient care and infrastructure. 🔗 medicine.washu.edu/news/drug-to...

Development of Simple Risk Scores for Prediction of Brain β-Amyloid and Tau Status in Older Adults With Mild Cognitive Impairment: A Machine Learning Approach url:https://academic.oup.com/psychsocgerontology/article-abstract/doi/10.1093/geronb/gbaf085/8125623

Genetic studies reveal protective variants that delay Alzheimer's, offering insights into new therapies. Be sure to check out our new review on protective genetic variants in Lancet Neurology, along with the editorial that features this research! www.sciencedirect.com/science/arti...

UPDATE: More than 5,000 homes were impacted, and 38 people were injured after an EF3 tornado tore across St. Louis. via @stlpublicradio.bsky.social

❌ FALSE: “For 20 years…we were directing Alzheimer’s research to one hypothesis. And any other hypotheses were shut down.” - Sec. Kennedy Over the last decade, less than 14% of new National Institutes of Health (NIH) Alzheimer’s projects focused on amyloid beta as the therapeutic target. 🧵(1/4)

The Wash U lecanemab paper is a hard act to follow. But here’s a combo experience with a private clinic and U Wash. link.springer.com/article/10.1...

We have been trying to learn everything we can from our experiences with amyloid-targeting treatments to improve patient care. We present the findings from our first 234 patients treated with lecanemab in JAMA Neurology: ja.ma/42TLKzx #ENDALZ @WashUNeurology

Check out a great podcast featuring Joe Therriault explaining how to diagnose Alzheimer's disease by integrating the clinical impression with plasma biomarkers: pca.st/episode/b729... He makes PPV/NPV so easy to understand! From his recent paper: rdcu.be/eldzt

Thank you @60minutes.bsky.social for giving the NIH freezes, termination, and proposed budget cuts the attention they deserve. ALL Americans, regardless of party, will feel this impact to their health far beyond one administration. www.cbsnews.com/video/nih-cu...

WIth 94 sequential patients on lecanemab, what did we learn? www.vumedi.com/video/real-w...

Happy to share the work of Vincent Bouteloup, which has just been published in JAMA Neurology and presented this morning at the AD/PD Conference! jamanetwork.com/journals/jam...

Big loss today. Alzheon overall trial was negative. But there were provocative findings. www.neurologylive.com/view/valiltr...

Cuts made today by the Department of Health and Human Services (HHS) may undermine our nation’s response to the dementia public health crisis. Read our statement: bit.ly/43BtxHU.

The bipartisan BOLD Alzheimer’s program is at risk. Take action NOW to urge your members of Congress to defend BOLD and continue strengthening our nation’s public health response to Alzheimer’s: bit.ly/42cDeKt. #BOLDAlzheimersAct

‼️New publication on a novel plasma biomarker for tau pathology 🧠🧪 in @naturemedicine.bsky.social led by Kanta Horie & @gsalvado.bsky.social: 📖 www.nature.com/articles/s41... In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).

We now have a blood biomarker that is even more strongly associated with tau PET and cognitive symptoms than even p-tau217! Plasma eMTBR-tau243 will help us to understand whether cognitive impairment is likely to be related to Alzheimer's pathology. #ENDALZ www.nature.com/articles/s41...

Projects on antibodies, genetics, and #dementia have been cut simply because—as far as scientists and #NIH officials can tell—their titles or descriptions mention words such as diversity. #Alzheimers #health #science

Donanemab: Appropriate use recommendations www.sciencedirect.com/science/arti...

Alzheimer's Research Caught in Trump Funding Delays www.medpagetoday.com/neurology/al...

“The motivations behind the removals from the agency’s boards of scientific counselors remain unclear. But among those being terminated are non-U.S. citizens, women, scientists from underrepresented racial and ethnic groups…” www.statnews.com/2025/03/24/n...

Large-scale Plasma Proteomic Profiling Unveils Novel Diagnostic Biomarkers and Pathways for Alzheimer's Disease

At this point beating up on Piller seems beside the point, but his book poisons the discourse. This response says it all. Kudos to Grill and Rabinovici. jamanetwork.com/journals/jam...

New report shows that NIH grants fueled $95 billion in economic activity and 407,782 jobs in 2024. That's not to mention the countless lives that biomedical research has saved. Show me a better investment than that. www.forbes.com/sites/michae...

#TobRegSky #PedSky #MedSky #EpiSky #addictionsci #policysky #polisky #academicsky #neuroskyence #painresearch #PCCM 🧪🛟 At Duke, research on cancer cures is coming to a hold. Universities are facing big cuts to research funding. At Duke, it’s a time for ‘damage control’ apnews.com/article/trum...

Excellent story in the Guardian about funds for Alzheimer's disease research centers being held up by the Federal Register-Advisory Council issue. www.theguardian.com/us-news/2025...